Partner Therapeutics Files sBLA for BIZENGRI in CCA
LEXINGTON, MASSACHUSETTS, USA, April 14, 2026 Partner Therapeutics, Inc. has announced the submission of a supplemental Biologics License Application...
AI in Healthcare Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
LEXINGTON, MASSACHUSETTS, USA, April 14, 2026 Partner Therapeutics, Inc. has announced the submission of a supplemental Biologics License Application...
SHANGHAI, China, April 1, 2026 Shanghai Henlius Biotech, Inc. announced that the China National Medical Products Administration (NMPA) has...
WOBURN, Mass., April 1, 2026 CanWell Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has granted...
NEW YORK, April 3, 2026 MiNK Therapeutics announced that new Phase II clinical trial data for its investigational iNKT...
HORSHAM, PENNSYLVANIA | January 27, 2026 — Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA)...
